AGEN$3.33
$3.3483
Chart
Performance
Key Stats
AI AGEN Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldAgenus Inc. (AGEN) demonstrates significant long-term thematic potential in cancer immunotherapy, but faces considerable fundamental challenges with profitability and cash burn. Technicals suggest a mixed short-to-medium term outlook.
Thematic
Agenus is at the forefront of the immuno-oncology space, with a diverse pipeline and innovative platforms addressing significant unmet needs in cancer treatment.
Fundamental
Agenus faces significant financial challenges, including consistent net losses, negative free cash flow, and a substantial accumulated deficit, which are critical concerns for investors.
Technical
The stock's recent performance shows a sharp decline from its 52-week high. Technical indicators suggest bearish momentum and potential for further downside in the short term.
| Factor | Score |
|---|---|
| Immuno-Oncology Pipeline Advancement | 85 |
| Biotechnology Innovation & Platforms | 80 |
| Market Demand for Cancer Therapies | 90 |
| Partnerships and Collaborations | 75 |
| Regulatory Landscape & Approvals | 50 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 15 |
| Balance Sheet Health | 5 |
| Cash Flow | 10 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 45 |
| Moving Averages | 30 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong Short-Term Performance
The stock has shown significant positive performance over multiple short-term periods, with a 25.21% gain in the last month and a 65.56% gain over the last six months. Year-to-date performance is also strong at 92.88%.
Very Low P/E Ratio
The trailing twelve-month (TTM) Price-to-Earnings (P/E) ratio is exceptionally low at 0.201, suggesting the stock may be significantly undervalued relative to its current earnings.
Bearish Points (8)
Negative Earnings and High Surprise Misses
The company has consistently reported negative Earnings Per Share (EPS), and recent quarters (Q4 2024, Q3 2024, Q1 2024) have shown significant 'surprise' misses, indicating earnings have fallen short of analyst expectations.
Negative Net Margin and Gross Profit
The company reports negative net margins across all periods analyzed (e.g., -219.6% in Q4 2024) and a negative gross profit (-$52.55 million in Q4 2024), indicating significant operational inefficiencies and a lack of profitability.
Calendar
August 2025
11
Next Earnings Date
H: $2.87
A: $1.35
L: $-0.78
H: 99.10M
A: 49.71M
L: 25.00M
Profile
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Seasonals
Price Target
11.50 USD
The 39 analysts offering 1 year price forecasts for AGEN have a max estimate of 25.00 and a min estimate of 6.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Major direct competitor in immuno-oncology with market-leading checkpoint inhibitors (Opdivo, Yervoy), directly overlapping with Agenus's pipeline focus.
Weight: 95
Dominant player in immuno-oncology with Keytruda (Pembrolizumab), a direct competitor to Agenus's checkpoint inhibitor development.
Weight: 90
Strong immuno-oncology pipeline including a key checkpoint inhibitor (Imfinzi) and a focus on combination therapies, a core strategy for Agenus.
Weight: 90
Key player in oncology and immuno-oncology with Tecentriq (Atezolizumab) and a broad pipeline of targeted and immunotherapies.